<SEC-DOCUMENT>0001193125-14-328277.txt : 20140902
<SEC-HEADER>0001193125-14-328277.hdr.sgml : 20140901
<ACCEPTANCE-DATETIME>20140902101253
ACCESSION NUMBER:		0001193125-14-328277
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140902
FILED AS OF DATE:		20140902
DATE AS OF CHANGE:		20140902

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		141076662

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d785005d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13A-16&nbsp;OR&nbsp;15D-16</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated September&nbsp;2, 2014 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-36421 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>AURINIA
PHARMACEUTICALS INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of Registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>#1203-4464 Markham Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Victoria, British Columbia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>V8Z7X8 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(250) 708-4272
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address and telephone number of registrant&#146;s principle executive offices) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F&nbsp;or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form&nbsp;20-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;Form 40-F&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form&nbsp;6-K&nbsp;in paper as permitted by Regulation&nbsp;S-T&nbsp;Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K&nbsp;in paper as permitted by Regulation&nbsp;S-T&nbsp;Rule 101(b)
(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file
number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: September&nbsp;2, 2014 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Aurinia Pharmaceuticals Inc.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dennis Bourgeault</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Dennis Bourgeault</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">News Release - Aurinia Pharmaceuticals to begin trading on the NASDAQ Global Market</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d785005dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g785005img001.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>NEWS RELEASE </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Aurinia Pharmaceuticals to begin trading on the NASDAQ Global Market </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VICTORIA, BRITISH COLUMBIA</B> &#150; September&nbsp;2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>, 2014 &#150; Aurinia Pharmaceuticals Inc.
(the &#147;Company&#148;) (TSX: AUP) today announced that the Company has received approval by the NASDAQ Listing Qualifications Department to list its common shares on the NASDAQ Global Market (&#147;NASDAQ&#148;). Trading will commence today,
September&nbsp;2<SUP STYLE="font-size:85%; vertical-align:top">nd</SUP>, at the opening of the market under the trading symbol &#147;AUPH&#148;. The company&#146;s shares will continue to trade on the Toronto Stock Exchange (&#147;TSX&#148;) under
the trading symbol &#147;AUP&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are very pleased to have our common shares listed on both the TSX and the NASDAQ exchanges,&#148; said
Stephen Zaruby, President and Chief Executive Officer of the Company. &#147;The listing on NASDAQ is a significant milestone for the Company and represents the culmination of a series of strategic restructuring steps undertaken by the Company.
Management believes that by listing on NASDAQ, a premier U.S. stock exchange, the Company will increase awareness and provide greater liquidity for investors and institutions.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>About Aurinia </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia is a clinical stage
pharmaceutical company focused on the global nephrology market. It is currently enrolling patients in its Phase 2b clinical trial to evaluate the efficacy of its drug, voclosporin, as a treatment for lupus nephritis (&#147;LN&#148;). LN is an
inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Voclosporin is a novel and potentially best in class calcineurin inhibitor (&#147;CNI&#148;) with extensive clinical data&nbsp;in over 2,600 patients in other
indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic
relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aurinia also has development and
commercialization partners in Canada, Israel, South Africa and Greater China. Visit www.auriniapharma.com, www.sedar.com and www.sec.gov for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stephen Zaruby </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">President&nbsp;&amp; Chief Executive Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250-708-4293 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>szaruby@auriniapharma.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael R. Martin </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Operating Officer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250-708-4272 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>mmartin@auriniapharma.com </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g785005img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g785005img001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`2P"Y`P$1``(1`0,1`?_$`,4```(!!`,!`0``````
M```````*"0$'"`L"!08#!`$!``(!!0$!``````````````$(!P0%!@D*`P(0
M```&`0("!04'"1,-``````$"`P0%!@<`"!$)(1(3%0HQ))6E9D%1TQ15MGB!
MD<$B(T46MSGP87&AL=$R8C-3)36U=A<W=Q@ZX?%RHD.#HS2DM)97.!$``@$#
M`@0$`P8%!0````````$"$0,$!08A,1('05%A$W$B"(&A,D)B"9&QP5(4(R05
M%A?_V@`,`P$``A$#$0`_`'^-`&@#0!H`T`:`-`&@#0%!\@\>C04KP/(7.^4K
M'$&>S7^U5^EUU-\PCE9ZSRK*%B$GTFZ391[960D%4&J2KUVL5-,#&#K',`!K
M09VHX6F6/\K.N6[6-U*/7.2BJO@DVS==%T+6]R9O_':!BY&7J'3*7MVH2N7'
M""K)J,4VTESHCT+)]'RC-M(1KQI(L'R1%VCYBNB[9ND%`ZR:S9R@91%=(X#Q
M`Q3"`ZU%FY:R+<;]F4;EOG&49*2Y<TUS-OR,:]BWIXF5;G;O1;4H2BXN+7-2
M3HT_1T,-K)NM3A,WLZ6C&(N<>-#&@[!9"'`SA"PK+)E!XW^V`AHN)5`$%@X<
M3"8Y@X]0`&BFZ?K#LZ%WZL;!M8=N>Q8TL9&5^97Y2HI1_1%_)+UJS/FD=D,G
M4.W,]T.XX;AE_J6K#5$[,5QJW^>2^:/I1>)F<*R"2(N#JI)H%)VIESG*5($Q
M#K=J90P]0"=7IX\>'#5[K$GDQA/'I*W-)QZ>-4^*:ISKX4*]9%ZUB6IW<N<;
M=FW7JE-J*27.K?)+U.BKMNJUO2?N:K8(>QM8N17B9!U#2#62;LY1L1,[J-76
M:**)INT$U2B<@CUB]8..M5?Q,C#N*&1:E;E)5XJALF@[HV]NNU<R=MYN-FXU
MBZ[<[EBY&Y&,U^*#<6UU+Q/2EX=/#AY?<^SKX1?4NKS-^K5OE4Y:DD-`&@#0
M!H`T`:`-`&@#0!H`T`:`-`&@#0!H"@^3WM"'5KAS(3N?%WX\V<5^!C2G[LG,
MQ5!&=4(7B!6[1A-NV*9S"`E`BL@F3H'H$0#5>?J465/M][&-7HEF6G*E:\*T
MY>I>;]OU:?'OF\K+2=ZWI61[=7XMP3X>/`@?VA[SL^[)FB[J#L4O:<5%;J=^
M8MG7SIW"BFH4"_&*F=T=56K3J8G^Y';]5L<_[LF<O2'`/I+V]W![H=S,'M#M
MO,:AJT;D4[K;A:I'C-?F71S73XE\OJ?[/]K=][?O;JSL.UB;BQ915N]8C&W*
M?'\-U125R,GP;DG))\&F3UUC*&"[I@`-T3.R,T<1FKK^T2]@D>Q(ZA2QQSIS
MD/+,P`RY+)&RH&9G:AUE%70@!.MVA!&=X?0EO31.^U[LQJ6G7KV^[F>H6VE7
MW(SEU*_&7C'I?N/CP7DSK\_[!J>)E+0J?[F-(*"K1JGRT_31<_+X&*<GO"R)
MNMQ?#3$&ZFJ9C=(TG#1U72>&3D9)I!/%F+=];'K4Q3N7;MDBFH9L`]@EUNJ/
M6-]N/;EC=A;?8.6-L;<5Q9VX\/`LN=SFG*44^F->#4.2?-GFB_="W_W=TGO=
MG]JL3-EA;.A8L7XV\=N"NROQ<Y>Y.-)-JM.FO3Z&<_*>!^TI&8HU4>M'H7YH
MZ:&X&*F"[N*(#DA0Z0ZX`D01_P!+6)^Z?LRU&Q.'"?11I4,H?MEK5<3M]K.#
MGU_PUFPG&56ZSDGU5;\>"J2U%#R\/='_`"?8UBB*I%+R.SFE/#B<M2`T`:`-
M`&@#0!H`T`:`-`8BY+W_`&QS#-UE\;Y;W>[;L:9!@#LTYVE7G,M!K%HAU)!H
M@_9$DX.8G6DBQ.[8NDUDP43*)DU"F#H$!T!E='2+"78,96*>M9*,DV;:0CI%
MBX2=L7[!Z@FY9O6;I`QT'+5TW5*HFH0QB'(8!`1`=`?LT`:`-`&@#0%!\@\=
M`89;_,&/]PVU;)N/X%L#RUMF3.W5!MU0,HZL53=)RS5BB`\1!>3;)*M2"'2!
MEPX:X9OW0X;CVME8+CU3IU17ZH<5_4S%V#W[_P";]T=,W%<FH82N>S>D^2M7
M:1DWZ+@WZ)BLSG`C^WXVEDV+50KT[`5#-3ME"JHKLU>+MBL0P`JFY*=(Q3%'
M]B(<!UM'T)9N+VS^IS0MQZG%*S:E=L4?!IW8],7_`!?`[1.[6];6=MR\H7(N
MS+HFJ.JE'\2:IS^/D6K@:EFF'PC;=KS,LDCC:WY/KV3YF+!4PM^\*_%KM5(\
MJ9N)RQ4J[^)/%TP``,X8IG$.(B.O1WJEOMMJ?='$[T9,;;W5A:?/%MRHJUG)
M-7:\^N,>J"\U+T136[D:3?UJUN&72\FW9=N-'SJZMOX<N/)$L.WW"CK&FVJO
MHRJ:B*SY27EU4SE`A@+*R!Q0,W`P&%/@W(F<.CW>(AJ@????-G=7<W.U*S-3
MMV[=N":Y)P5&JGGA_<'TS`WSW[U'<4%U8]NS8L**XN4[<>EJ/JV3([',4O<6
MX0:=\-?BD[=IJ1N;YJHF"2[%I)`BC$,ER<"F*JG&MB*&*(<2'5,7W-4SW=J2
MU'6)3A+JM05$_P"9:+Z1^VUWMSVCQK.=;E;U+4;TLJY&2I*"N)=$&O#I2^\S
M(#R:XK&M%7F6@X^)74@\W<+C4\?5:P7B]62#I]-J<2]GK/:;+)LX6OU^$C4#
M.9"6F):05091T<Q;D$ZJRIRIID`1$0#0%K\([GMN.Y5K8'VWG.N)LWLZHX8-
M+.ZQ7?JS>V]?<RJ3A>,;S"M;DI$D<L_1:*F1*J)14*F82\>J/`"^F@#0!H`T
M`:`-`6ZR[E"H82Q;D7,>0))*(H^+*/:<A6V26433(SKU0A7L[++@98Z:0J%9
ML3`0!,'6.(![N@--ED+%.?.9VSYH_-&<?&5VF'KY3<LW^/.V7=G/"9OR3(5>
M)@(MT`"FFAC>KMFYS@8?N<:SX^X&@-C;X8??6.]#E<XQKUGF#2F6=JSG^[S?
M3.7(N)%["UEHDYQ;/N>N`*B1_C]PT9BH83"JZC5S"81X\`&)0^MH`T`:`-`&
M@#3X`^1@#@'EX_H>_P#YM?F32^2E8OF0VG'C5)O[3"[(^T:MREFE+M26S2+>
MSRJKZQ5T2D0CI"36_P"8EH_@`)LWCT>EPF(`FL81-T&$>/$,W:ZLZM9UW19>
MSJ%FZIIKAQC1I_&O$S=M?O!JF#I,=OZ[*61I]N/1;N/C*$/[7YI>#\N#+6,]
MGT$LZ2,XC@04Z_7<E^)D%8I2F`%R)F$"J'Z!ZI1]WC[VK=:=WSUO)T2,,BY*
M.6K?2ZM_B2I7[>9Q+<.\IX>-DW=/E*<&G[:7-M\J?#R,F8C!$*]=Q2UB9MC0
MD'V'==<`A!;J@R,'Q`T@0OW,R*`)E$$>D#"`=;B`<-8FU'=69>C<Z9.5^Z_F
MGZO^I3C%[,VMQ[H6[MY4NQ5]WHV'QZ[E6T[GFE_:9$%+V90X=4"E`H%``X`!
M0X!T`'0'1Y`#7$).4Y<?,L%&,+2XI0LQ5(Q7)(^X='O_`%A']3CJ#Z+D5T),
M4]\^`)_=9LYW-;:JM.0U9L>=,*9!Q?"6&Q(O7$%"R=PKKV'9R4LA')JOU8]H
MJY`ZI42F4$H=`".@(@/#Z\F/,/)[J6YBN9<R]C++#C.-CQM-0CC&["T,DH9"
MDQ=J8O4I8;/'1YU%'BL^04@1`X`!#"80$0#0#%>@*<>GA^O^MPT!70!H`T`:
M`5!\7EO>_NY<N6/VVUF7^)9"WFW`M+<(-U$P>(XAH:L9:,D.NKU@52;2C]6'
MB5!`."B$@L3I#K<`.Y\/1ROZ76^1S,8WR_6$0EN8U3[Y>LI%>-@,]3HF1JXZ
MI^+&Q".40,B:)HZ;>99\"CV#V044*/$0'0"V/AK,]6_EE<YK+O+]S2\4B(K-
MEEM>V:RMW8J-6"6;L5V":5Q=.)(*+]FF-D.E(1;01ZYE!G$2AQ$0X`;/,/(&
M@%HO%"<P3=9RZMG&!<J[2,CHXTO%TW-1F/;',+5BLVDKZJ.,6Y+LBL:#*TQ4
MLR;B:7K[17M4TRJAV?5ZW5,8!`D6Y*VXO+N[7E>;1=Q.>;.2YY;R?2K3+76S
M$B8J#++/XW)EWKS-8(J$:,8MIV43#MTA!%),IA)UA#K".@)#\FR\C7\;9!GX
MA<&TM"4>V2\8Y,F14&\C&P+]ZR7%)4ITE`2<HE-U3`)1X<!#AH!-+PM_-TW\
M<QG<AN:H6[K,S?)M6Q[A"O6^IQJ5'I%5-&V![?&$*Y?"ZJL#$.7/:1JYR"FJ
M8Y`X@(``AH"6[Q(F]?<AL&Y<XYYVM7M+'>3PSGC.G#8%J]7[,7\'K"A9%)5B
M$=98Z4C0%R>/2^Z=EVA0*/5$.(Z`4TN//DYR?,;Q[MQVG<N%/+5GS95,+15F
MW8Y9P_081C?[MDJ0=O%9%%O+%BD*_C'']69+-F8.6XL#R<CVH@IV1$R'+@.0
MPUX<"^\ZFUS^Z2F\TU[E%*G8F0H\%C^.SK0XZ(R*_NUE!S+2+R%O+*-CU;?4
M(RML$NT4,K(IBY?$ZJY1(<HQ1#QJ8&;.^<5S!\J^(ZNFPF\9L;3&UV)W"[H:
M0RQZ6@T9BJC6,<U?(<C4(X+*R@D;&8T6[@FIC*BZ,=;LQ`XF`PAHU4?R&G.:
MAFO).V_ET;R<\8?GB5?*&*<#W:Z4:PJ1S"7)#V*(9%68/CQDH@ZCGP(G']S6
M3.F;ATAJ4DN7BQ3C7Q$9-JOB>N9[E#;@AMJQ)57^[+F5YHS+-,L?V$F,*^>$
MQGB)I6J\9J>/IU8CH6%M5K>3I9%;XQ)`2*BF29EW@J%ZB>A%/O/;Y?P5XRO&
M-.E=Q<[FK+,[W-'K66<H&,LJX7M=AA8Y),SMT5/$%?9*P$Z+%`1$S.,;2*_`
MH\$S"`Z$DK?AQ?$*Y1YA]]G]F.\QI6PW&0-0D+?C3)E;A@K265H6K"F2WP%K
MK;8>ZXR^P3)8K\JS%-JU>,T7`F0250XK`,6\R;+E_P`!;`MXN;<531*YDG%6
MW;*=ZHT^I'LI4D/9JY59"3B)`T;)(N&#XK9XW*84EB'3/PX&#AH"!'PL/,QW
ME\Q^A[PIO=]E1#)[_%ENQ'%T==&HU*J=SL[/"W5U-I&)5(>(3>@[6B&Y@%8I
MQ()!ZH@`B&@)6^<GS8<;\H[:P.:[)7/Z0\H7F<5HV#L5A(#%)W&Y!'J2+R1G
M9--)=>+IE48%!Q)+I)G6,*B+=(`5<$,4!0W!^;_%?\Y"LN=P&WK)##;MM^GI
M&59U&3@7U(P10Y)-D^7:.6].>2,9:,N6MC&.45&QI+M7+8RR1R"N*A1*4"U^
MYC+OBN^3[%1V=<^9OM63<+,)AJRF+8_F*!N&Q0B]DG!&S&/NJ;J';W>I,99T
MJ5%!PJ6-2.L<I$UP5,0!`<AY(O-<A^;=L]+FQ[5XR@YAQ]:W&-<WT:%7=N8&
M-MK:/92\;8*NJ_.L_P#P6MD(_3<-TUU%56JY'#<RJHH=J<"8[B/O#^E^OH`'
MR:`U6//HW.8^YC'/:@,)73*==Q_MAP#?J3M;ELC62:3C:?5X&$LX2.X&\+2S
M<BH("E.NY)FFJ7M#+%C&_4X@)0T`^94N=7R8*-5*S2*KO]VOP]8IU>AJK7(E
MI>$$VL7`UZ-;Q,1'-DR-"D(W8Q[1-(A0```I0X:`U^GB-,K[7'G-`I&^KE\[
MCL993=9$AZ)DFRR>*YQ*65HF=L0/XR+:2TFFB5`S8\_$0D2\(/#[NNBX$1$1
M'0&S0V#;LJKOCV<;=]U5240*RS)C2OV.8CD3E-^#]S2;]UWNL*=41X*URXL'
MS+IX=8$0,`<#!H!8_P`;'^3RVN?3.AOQ'YFT!+OX<7\B=L&_LXN_XYLE:`EM
MS/\`U/97_LUO7S7E-`:[GP1G_P!@[T/HUU3\:$5H">_QA8\.4*H/O;F\+C_T
MMRT!T?@],!U/'/*Q>9E8Q+9&\;A,X9!E[-.B1$[]Y`X^=)4:IQ`N0`5PCHT\
M<^<)HB8"%6>JG`H"<PF`:\`.`!^=P#WOJZ`UE?+V_P`7_DCZ5^]KYE99T`\%
MSP_R1',-^B]DG^3`T`JCX(G!%.?'WQ;E9&+8/KS!K8MPS5Y1PW35?U^`F6MB
MM]L3C5CI"+8+$[CXPK@Q3=8Q6)"_L1-U@-@``</S?F'0&L"V+5Z.Q/XO.R4N
MC)%@J\UWC[L(A*/9$(W;$BY>F92DWD<F@D!4DF9G*P]5,H`0I0````#AH!]K
MG%?DJ^83]$?.'S%E]`*S^![_`*K>8+P\OX?8$^;>1]`,H<SCDS[..:R?'$KN
MKD,P,'F'8>TQ]*D<;Y&3J+.&:VEQ%OI]\\B9:$L5<=.U^XFP'<JM>T[%$I!-
MU0#@!TR?,]Y.G+\QKC[;>ZWN;<Z97L'TJM8Q@:?`W=A?;!#1-,B6T"S;S,3C
M5G8GR<T=)@"CL5&Z:JK@YU#EZQ^D"#3F]^)7Y3N=-C&[#:MB:U9*SM><UX>N
M6.*DM`XLF86E1=KFXI4*M:):>OQJL<(RMV)-J],9HV=.0,@`IIB8`T!9OP/"
MRPXCYAK4RIS-T<C[>5TD>N(I)KN*QE5-PLF3CU2G7(U3`P^40(7W@T`]IH#!
M'F;;PH;87L1W*[II1=J61QIC:7/2&3EPF@$SDJQ`G6<<PZ8J&**@O;C+LP4*
M3B?L"J&`/M=`:Z3P_7(UH_.5;;I\^;K<A9=K-)I]O@J_`6#'[Z`83=ZRK;!D
M[A?WLM(V2NV%LY1A8]PQ45*DD0YUY4#"8.IU1`9`#P6G+7_]Z[O?_+,7?J?T
M6<?T]`86\Q/PB&U;`&R;<9G/:_E+<?<LU8>QU*Y)J]1N\Q19BOV9A3C(S=MB
M%F4#1(*54D%J@T?'9=DX*(O")%$!*8V@.]\%IOI/8*#N$Y>]PE^U?T)__>#P
MPU=.`%0*G9';"OY2@8\AS]8&D/9SQDD5,A>`*R[DX^7H`R8\:\U<+<NW;(ND
MBJH@TWF0)W2I"B8C<BV%<QH)F5,`"!`45.!0$?*8>&@)7O#:2T?*\D[8IW>Z
M3<]V4G($2^!,P&%M(,\S9'%PU4X"/543!4HB'EX&#0$H&[K(U:Q!M6W(Y1N+
M]M&5B@8,RI:YMZ[6!!!)C"TF;>J$,J(#P.N*0)D``$QCG```1$`T!K^/!&@`
M;P=Y_#CT[::H(_H_THQ?V-`3V^,,_)"J_2:PO_VMRT!>CPI'Y%?;W_/S.?XT
MK%H!CK0&LJY>W^+_`,D?2OWM?,K+.@'@N>'^2(YAOT7LD_R8&@%Q/!!#QVW[
M[O[;L3_,.?#[&@'CM`:Q[:[_`(QZV?37W._B\R9H![WG%?DJ^83]$?.'S%E]
M`*S^!Z_JMY@O\_L"?-S(^@/$^,'YF^=*;D3%_+<PC;;!0J?:,=165<Z/ZJ^>
M0\_D0]IGI>%I&.G$FR40=$I[-*`6>O6R:@$D7#E$BP"FWZJ@&3NQ_P`&_LPA
M<2T*V;T,C9?RWENQUB#G;;4:'9F&.\:U:6E&3>0<5R+7CHE];)TD2*XME7QY
M!N5T<G:)HHE$"B!E'S*^4ARF>7-RHM].4L5[3L45B]1^VZ]TZH9,NQI/(%^9
MW?(#`M%J+NN6&_R=@<P=A-/V!MV2D65HJ`E$P</MC:`CX\#O_53S$?[0=N8?
M6K67-`/<Z`2Q\7U*[O\`->.]N&S+;#MPW&9AI\K-R.<\T6#$.',CW^M@O7P=
M5G&E0DYNHUN5C2O$WCR5DW#(ZHJ%%)FJ)2\""8"<OD.[*G>P_E>[:,.V6OO*
MWD^RUD^8<QQ<FU.REV&2<H"G8I*$EVBR:;AK(U*&48PRJ:@=<AX\0$`'H`"8
M/0'X9.,83,<_AY5FVD8J59.XV3CWB15VCY@^04:O&;E$X"15NY;*G(<H@(&*
M80'HT!JX,4[--]?)UY[W](&%=IFZ7)&W?%VXZ5B$;AC3!N4+C3[;M>RPX!&1
M9-K#7*M*P\LZKU"M!05(54>SEHL`$2&(`@`^#SJN7.KS2-@&1]N59F(VOY1;
M/X+*&%9R=!1O$(9&IWQE:+B9Q;L#N8Z*M40_>13A<$S&:?'`7$A^R$A@$--D
MW,5YROAZ!MVUS*^SJVW'#SBR2$]&8XRK4KHA7(2RR!R]YSV(LM4UO)P3N&L9
MDBK.4$323)57@J0J*QUC*`2$2F9^>AXE20AMN[C"CK8?R_):5BWV;;LTJMPA
M(>RP$2Z;R@L'5LO(1M@RP].NBF=C"0C9M&G=E35D![-,#D`N+X2+9WN/VO;W
MM\I\O;?<\XGI"^(&U4I-MRWBB[4&*MG=.76XLR1,Q9(&(BIA^O#M@<F(U.?B
MGQ.`=3@.@)D?%;8:R_G?E7J47"&*\C9BNH[B<1R_X(XNI5COUF[ICVUL*^E.
MXJM&RDIW>R,X3!5;LNS3$Y>L(<0T!=WPR>*<HX6Y0N"<?YBQQ>\47R+NN9W,
ME2LD5*>I%LCVTEDJ>>QSA[7;*PC9=J@_9JE51,HB4%4S`8O$!`=`3^:`UV&Q
M+:-NNK'BJ\@9TLNV3<#7\)N]SF\*;:Y@F\.Y!BL7N(6Q5#)[>`ET+Z^KZ%66
MC)Q=Z@1HN5T*;DRQ`3$PF#B`X_SD:=;\C<K+?A1L?56QWJZVG;?D&'K-0I\)
M)62SV*6=QX$:1<'`Q#9W*2LBZ/T)HH)'4./D`=`0">#CV[;@-O&W_>I$Y^P=
ME["$I9,Q8QD:]&Y<QO<,</YY@RI4XV>/H9G<(>'<2;1HX5*FJHB4Y$SF`IA`
M1X:`<KT!KI]M^T+=C#>+&L^>9?;'N"B\'+[P-QE@1S'(X<R$RQ:K`3%#R&UB
M9Q._N:\E55(B4=/$4V[@'8I+**D*0PB8`T`ZGS7ZI:;URS]]E,I%;GKC<+1M
M;S)!UJJ5:(?S]CL,U(TN5;1\1!PD4W=24K*/W*A4T4$$SJJG,!2E$1T`MAX-
MW;?N'V[XVWT,L_X'S'@]Y:+OA)U6FN7L9W/'#BPMXR`OZ,DO"(7"&AU95!@J
M[2*L9`#E2,J4#"`F#0'T\55R4L^[SY+&V^#:%3'V3LFXUHIL:Y@Q-7B(FN5D
MI$5*2,_5;I2&1UDEK',5US+O&KR,0ZSQ=JH@HV3.9)4A@,!ML?BK^8GM]QE5
M=OFY3EUVO-&8*#`Q],C;:HSR5BZ\V?N1F$7%J7NE.J#8U'5E[)H0'CEF#;XX
MJ!S]@0XF$P%Q,I[?>>SXD-EVVX_').7QLAH<9*WND8HEX.>A)K*&18V"E2TX
M%*W;5XR[7.3<R"WQ<LI*HQ,%%MESK-FZK@>!P+F>#WQ5N<VL9-WL81W&;8]Q
M&$T\AU[&]TJEFR;A_(],IDM*XUE;37;!!LK)/UYC6G,M\7N2#AL4C@QW+=)4
MR76*01T`]OT?MO\`7T!U7?<'T_PU%]/N=XM.`?H?=NC0%0G(,/OS%>D6GPV@
M*]^PGRS%>D&GPV@#OV$^68KT@T^&T!09R$'[\Q7I%IT_\;0%.^X/HXS,6/#A
MY9%G[G3Q_=>''CH"O?D&'DF8KTBT^RMH`&<@Q\LS%>D6@?5#@MY=`5[]@_EF
M*](M/AM`'?L'\L17I!I\-H`[]A/EF*](,_J?[;W-`'?L)\LQ7I!I\-H`[]@Q
M^_,5Z1:?#:`X]]P8#Q[YBO+Q_C!I[YA_?OVV@.7?L)\LQ7I!G\-H`[]A/EF*
M](-/AM`'?L'\LQ7I%I\-H"@SD&/WYBOJ2+0/=`?W[\[0!WY!\>/?,5Z1:</K
M=MPT`#.08\/X9BNCR?P@S]X0_?OS]`5[]A/EF*](,_AM`4&<@Q^_,5T"`_QB
MT]S_`'V@*=]PGRU%^D6?3T\>GBKTZ`Y=]PGRQ&>D6OPV@-#5YO[9>LM`'F_M
MEZRT`>;^V7K+0!YO[9>LM`'F_MEZRT`>;^V7K+0!YO[9>LM`'F_MEZRT`>;^
MV7K+0!YO[9>LM`'F_MEZRT`>;^V7K+0!YO[9>LM`'F_MEZRT`>;^V7K+0!YO
M[9>LM`'F_MEZRT`>;^V7K+0!YO[9>LM`'F_MEZRT`>;^V7K+0!YO[9>LM`'F
/_MEZRT!=CS/VZ]>Z`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
